Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma

Nanfang Hospital, Southern Medical University

Status: Enrolling

Conditions: Hepatocellular Carcinoma

Treatments: Diagnostic Test: diagnosed by traditional diagnostic markers（such as AFP or CT etc.）

Study type: Observational

Funder types: Other

Identifiers

NCT06623474

NFEC-2024-361

Details and patient eligibility

About

As one of the common malignant tumors in China, primary liver cancer, whose incidence rate and mortality rate are always in the top five, is seriously threatening the health of people. Therefore, early diagnosis and treatment of primary liver cancer are of great significance. In recent years, the incidence of primary liver cancer, which is caused by hepatic steatosis or metabolic dysfunction-related liver disease, is increasing year by year, and it has become one of the fastest rising causes in some developed countries. More and more studies have also confirmed that the levels of different kinds of lipids and their metabolites are correlated with the development of hepatocellular carcinoma. In this study, the researchers performed qualitative and quantitative analyses of various common lipid metabolites in plasma and liver cancer tissues of hepatic resection patients with hepatocellular carcinoma, collected tumor-related pathological data from the patients, and investigated the correlation between the lipid metabolites and the development of hepatocellular carcinoma, in order to provide a new idea for the early diagnosis and treatment of primary hepatocellular carcinoma, as well as for screening of hepatocellular carcinoma markers.

Enrollment: 900 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged 18-80 years old undergoing hepatic resection for hepatocellular carcinoma (diagnostic criteria for hepatocellular carcinoma refer to the guidelines for the diagnosis and treatment of primary hepatocellular carcinoma).
• Voluntary signing of informed consent

Exclusion criteria

• In the judgment of the investigator, they are not suitable to participate in this study.
• Patients with hepatic malignant tumors with invasion of the main portal vein and its first-order branches, the common hepatic duct and its first-order branches, the main hepatic vein and the inferior vena cava, or extrahepatic metastases.
• Surgery with biliary tract exploration or reconstruction in the presence of biliary obstruction.
• Surgery combined with splenectomy or splenic artery ligation
• Preoperative combination of cardiac, pulmonary, renal and other organs with major underlying diseases.

Trial design

900 participants in 2 patient groups

Patients diagnosed with hepatocellular carcinoma

Description:

Patients diagnosed with hepatocellular carcinoma according to the guidelines for the diagnosis of primary liver cancer

Treatment:

Diagnostic Test: diagnosed by traditional diagnostic markers（such as AFP or CT etc.）

Patients diagnosed with non-hepatocellular carcinoma otherwise requiring hepatic resection

Description:

Patients who can be excluded from the diagnosis of hepatocellular carcinoma according to the guidelines for the diagnosis of primary liver cancer but required hepatic resection for other liver diseases

Treatment:

Diagnostic Test: diagnosed by traditional diagnostic markers（such as AFP or CT etc.）